First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease. [electronic resource]
Producer: 20130314Description: 48-51 p. digitalISSN:- 1167-7422
- Androgen Antagonists -- adverse effects
- Antineoplastic Agents, Hormonal -- adverse effects
- Bone Neoplasms -- metabolism
- Cyproterone -- therapeutic use
- Estrogens -- therapeutic use
- Flutamide -- therapeutic use
- Goserelin -- therapeutic use
- Humans
- Male
- Neoplasms, Hormone-Dependent -- metabolism
- Orchiectomy -- adverse effects
- Practice Guidelines as Topic
- Prostatic Neoplasms -- metabolism
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.